Aquinox Pharmaceuticals Inc is a clinical-stage pharmaceutical company discovering and developing targeted therapeutics in disease areas of inflammation and immuno-oncology. Aquinox Pharmaceuticals Inc is a clinical-stage pharmaceutical company discovering and developing targeted therapeutics in disease areas of inflammation and immuno-oncology.
SEATTLE, Aug. 07, 2019 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc. (βNeoleukinβ), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein...
β’ Combined company capitalized with approximately $65M to develop novel immunotherapies β’Β Sophisticated computational platform enables new class of de novo protein therapeutics β’Β Lead program...
VANCOUVER, British Columbia, Nov. 07, 2018 (GLOBE NEWSWIRE) -- Aquinox Pharmaceuticals, Inc. ("Aquinox") (NASDAQ:AQXP), a pharmaceutical company discovering and developing novel drug candidates...
VANCOUVER, British Columbia, Aug. 08, 2018 (GLOBE NEWSWIRE) -- Aquinox Pharmaceuticals, Inc. ("Aquinox") (NASDAQ:AQXP), a pharmaceutical company discovering and developing novel drug candidates...
VANCOUVER, British Columbia, June 27, 2018 (GLOBE NEWSWIRE) -- Aquinox Pharmaceuticals, Inc. ("Aquinox") (NASDAQ:AQXP), today announced that the Phase 3 LEADERSHIP 301 clinical trial evaluating...
- Trial Will Enroll Approximately 100 Male Subjects in the US and Canada - VANCOUVER, British Columbia, June 11, 2018 (GLOBE NEWSWIRE) -- Aquinox Pharmaceuticals, Inc. ("Aquinox...
VANCOUVER, British Columbia, May 16, 2018 (GLOBE NEWSWIRE) -- Aquinox Pharmaceuticals, Inc. (βAquinoxβ) (NASDAQ:AQXP), a clinical-stage pharmaceutical company discovering and developing novel...
-Aquinox to Receive $25M in Upfront Payment, Potentially Over $100M in Additional Milestone Payments and Royalties- -Astellas to Obtain Development and...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
12 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
26 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
52 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
156 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
260 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.